Assessment of the coagulation profile in hemato-oncological patients receiving ATG-based conditioning treatment for allogeneic stem cell transplantation

Bone Marrow Transplantation

Volumn 34, Issue 5, 2004, Pages 459-463

  Inbal, Aida ^a,b   Lubetsky, A ^a,b   Shimoni, A ^a,b   Dardik, R ^a,b   Sela, B A ^a,b   Eskaraev, R ^a,b   Levi, I ^a,b,c   Tov, N S ^a,b   Nagler, A ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Allogeneic stem cell transplantation; Antithymocyte globulin; Circulating microparticles CD40 ligand; Coagulation

Indexed keywords

ANTITHROMBIN; BIOLOGICAL MARKER; BUSULFAN; CD40 LIGAND; CYCLOPHOSPHAMIDE; FIBRINOGEN; FLUDARABINE; HOMOCYSTEINE; MELPHALAN; PROTEIN C; PROTEIN S; PROTHROMBIN; THROMBIN ANTITHROMBIN COMPLEX; THROMBOPLASTIN; THYMOCYTE ANTIBODY;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; FEMALE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERCOAGULABILITY; IMMUNOSUPPRESSIVE TREATMENT; LIVER VENOOCCLUSIVE DISEASE; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOCYTE COUNT; THROMBOEMBOLISM; THROMBOPHILIA; THROMBOSIS;

ADULT; AGED; ANTILYMPHOCYTE SERUM; BLOOD COAGULATION; CD40 LIGAND; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POLYMORPHISM, GENETIC; PREVALENCE; RISK FACTORS; THROMBOSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 4544311018     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704609     Document Type: Article

References (31)

1. Dvorak HF, Nagy JA, Berse B et al. Vascular permeability factor, fibrin, and the pathogenesis of tumor stroma formation. Ann NY Acad Sci USA 1992; 667: 101-111.
2. Cavanaugh PG, Sloane BF, Honn KV. Role of the coagulation system in tumor-cell induced platelet aggregation and metastasis. Haemostasis 1988; 18: 37-46.
3. Hoffman R, Haim N, Brenner B. Cancer and thrombosis revisited. Blood Rev 2001; 15: 61-67.
4. Tempelhoff GF, Dietrich M, Hommel G, Heilmann L. Blood coagulation during adjuvant epirubicine/cyclophosphamide chemotherapy in patients with primary operable breast cancer. J Clin Oncol 1996; 14: 2560-2568.
5. Sletnes KE, Holte H, Halvorsen S et al. Activation of coagulation and deep vein thrombosis after bone marrow harvesting and insertion of a Hickman-catheter in ABMT patients with malignant lymphoma. Bone Marrow Transplant 1996; 17: 577-581.
6. Falanga A, Ofosu FA, Delaini F et al. The hypercoagulable state in cancer patients: evidence for impaired thrombin inhibitions. Blood Coagul Fibrinolysis 1994; 1 (Suppl.): S19-S23 discussion 59-64.
7. Gordon B, Haire W, Kessinger A et al. High frequency of antithrombin 3 and protein C deficiency following autologous bone marrow transplantation for lymphoma. Bone Marrow Transplant 1991; 8: 497-502.
8. Gordon BG, Saving KL, McCallister JA et al. Cerebral infarction associated with protein C deficiency following allogeneic bone marrow transplantation. Bone Marrow Transplant 1991; 8: 323-325.
9. Conlan MG, Haire WD, Kessinger A, Armitage JO. Prothrombotic hemostatic abnormalities in patients with refractory malignant lymphoma presenting for autologous stem cell transplantation. Bone Marrow Transplant 1991; 7: 475-479.
10. Harper PL, Jarvis J, Jennings I et al. Changes in the natural anticoagulants following bone marrow transplantation. Bone Marrow Transplant 1990; 5: 39-42.
11. Anderson ND, Wood Jr S. Intravascular thrombosis and leukocyte destruction in vivo by heterologous anti-lymphocyte serum. Fed Proc 1970; 29: 145-149.
12. Mee AD, Evans DB. Anti-lymphocyte-serum preparations in treatment of renal allograft rejection. Lancet 1970; 2: 16-19.
13. Simmons RL, Condie R, Najarian JS. Antilymphoblast globulin for renal allograft prolongation. Transplant Proc 1972; 4: 487-490.
14. Kimball DB, Rickles FR, Gockerman JP et al. Procoagulant and platelet aggregating properties of anti lymphocyte sera. J Lab Clin Med 1976; 87: 868-881.
15. Gruber SA, Pescovitz MD, Simmons RL et al. Thromboembolic complications in renal allograft recipients. Transplantation 1987; 44: 775-778.
16. Weber M, Kroger N, Langer F et al. Non-overt disseminated intravascular coagulation in patients during treatment with antithymocyte globulin for unrelated allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2003; 31: 817-822.
17. Hoffman M, Monroe DM, Roberts HR. Coagulation factor IXa binds to activated platelets and platelet-derived microparticles: a flow cytometric study. Thromb Haemost 1992; 68: 74-78.
18. Barry OP, Practico D, Lawson JA, Fitzgerald GA. Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. J Clin Invest 1997; 99: 2118-2127.
19. Mesri M, Altieri DC. Endothelial cell activation by leukocyte microparticles. J Immunol 1998; 161: 4382-4387.
20. Galli M, Grassi A, Barbui T. Platelet-derived microvesicles in thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Thromb Haemost 1996; 75: 427-431.
21. Mallat Z, Benamer H, Hugel B et al. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 2000; 101: 841-848.
22. Joop K, Berckmans RJ, Nieuwland R et al. Microparticles from patients with multiple organ dysfunction syndrome and sepsis support coagulation through multiple mechanisms. Thromb Haemost 2001; 85: 810-820.
23. Walenga JM, Jeske WP, Messmore HL. Mechanisms of venous and arterial thrombosis in heparin-induced thrombocytopenia. J Thromb 2000; 10 (Suppl. 1): 13-20.
24. Hughes M, Hayward CP, Warkentin TE et al. Morphological analysis of microparticle generation in heparin-induced thrombocytopenia. Blood 2000; 96: 188-194.
25. Greer IA. Thrombosis in pregnancy: maternal and fetal issues. Lancet 1999; 353: 1258-1265.
26. Buhlmann JE, Noelle RJ. Therapeutic potential for blockade of the CD40 ligand, gp39. J Clin Immunol 1996; 16: 83-89.
27. Miga A, Masters S, Gonzalez M, Noelle RJ. The role of CD40-CD154 interactions in the regulation of cell mediated immunity. Immunol Invest 2000; 29: 111-114.
28. Jacobson DW, Gatautis VJ, Green R et al. Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: sex differences and correlation with cobalamin and folate concentrations in healthy subjects. Clin Chem 1994; 40: 873-881.
29. Salomon O, Steinberg DM, Zivelin A et al. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism. Arterioscler Thromb Vasc Biol 1999; 19: 511-518.
30. Frosst P, Blom HJ, Milos R et al. Candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-113.
31. Starzl TE, Boehmig HJ, Amemiya H et al. Clotting changes, including disseminated intravascular coagulation, during rapid renal homograft rejection. N Engl J Med 1970; 283: 383-390.